Use of ACE inhibitors and ARBs in hypertensive women of childbearing age

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 5, 2008, Pages 507-511

  Martin, U ^a   Foreman, M A ^a   Travis, J C ^a   Casson, D ^a   Coleman, J J ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adverse effect; Angiotensin converting enzyme inhibitor; Enalapril; Guidelines; Hypertension; Infants

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BARRIER CONTRACEPTION; FEMALE; FETUS MALFORMATION; GENERAL PRACTITIONER; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PREGNANCY; PREGNANCY OUTCOME;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; CONTRACEPTION BEHAVIOR; FEMALE; GREAT BRITAIN; HUMANS; HYPERTENSION; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; RISK; TERATOGENS; YOUNG ADULT;

EID: 52049123826     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00938.x     Document Type: Article

References (14)

1. Shotan A, Widerhorn J, Hurst A et al. (1994) Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. American Journal of Medicine, 96, 451 456.
2. Barr M Jr. (1994) Teratogen update: angiotensin-converting enzyme inhibitors. Teratology, 50, 399 409.
3. Miyazaki Y et al. (1999) The renal lesions that develop in neonatal mice during angiotensin inhibition mimic obstructive neuropathy. Kidney International, 55, 1683 1695.
4. Lip GY, Churchill D, Beevers M et al. (1997) Angiotensin-converting- enzyme inhibitors in early pregnancy. Lancet, 350, 1446 1447.
5. Chung NA, Lip GY, Beevers M et al. (2001) Angiotensin-II-receptor inhibitors in pregnancy. Lancet, 357, 1620 1621.
6. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. New England Journal of Medicine, 354, 2443 2451.
7. Quan A (2006) Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Development, 82, 23 28.
8. Williams B, Poulter NR, Brown MJ et al. (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of Human Hypertension, 18, 139 185.
9. NICE. Hypertension: management of hypertension in adults in primary care. Clinical Guideline. Reference: CG034 2006.
10. BBC (2006) 40% of pregnancies 'unplanned'. http://news.bbc.co.uk/1/hi/ health/3515400.stm (accessed 7 December 2006).
11. Saji H, Yamanaka M, Hagiwara A et al. (2001) Losartan and fetal toxic effects. Lancet, 357, 363.
12. Friedman JM (2006) ACE inhibitors and congenital anomalies. New England Journal of Medicine, 354, 2498 2500.
13. Tabacova S (2005) Mode of action: angiotensin-converting enzyme inhibition-developmental effects associated with exposure to ACE inhibitors. Critical Reviews in Toxicology, 35, 747 755.
14. Alwan S, Polifka JE, Friedman JM (2005) Angiotensin 11 receptor antagonist treatment during pregnancy. Birth Defects Research (Part A): Clinical and Molecular Teratology, 73, 123 130.